S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:GEMP

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.85
$5.30
50-Day Range
$0.30
$6.38
52-Week Range
$0.24
$1.49
Volume
60,248 shs
Average Volume
127,174 shs
Market Capitalization
$76.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GEMP stock logo

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.


GEMP Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
BiVictriX Therapeutics makes 'fundamental step forward'
See More Headlines
Receive GEMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2019
Today
2/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GEMP
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
$-23,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$76.14 million
Optionable
Not Optionable
Beta
2.82
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Charles L. Bisgaier (Age 65)
    Co-Founder, Chairman & Chief Scientific Officer
  • Dr. Steven R. Gullans (Age 66)
    CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer
  • Mr. Seth Reno (Age 52)
    Chief Commercial Officer
  • Mr. Jeffrey S. Mathiesen C.P.A. (Age 58)
    CPA, Consultant
  • Ms. Amy Zaremba Rabourn
    Director of Fin.














GEMP Stock Analysis - Frequently Asked Questions

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.

What other stocks do shareholders of Gemphire Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Alexion Pharmaceuticals (ALXN), Clearside Biomedical (CLSD), Intel (INTC), Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT).

When did Gemphire Therapeutics IPO?

(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

This page (NASDAQ:GEMP) was last updated on 2/29/2024 by MarketBeat.com Staff